Bahram Valamehr - 07 Jul 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
07 Jul 2022
Net transactions value
-$518,686
Form type
4
Filing time
08 Jul 2022, 16:51:04 UTC
Previous filing
07 Jul 2022
Next filing
11 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $46,841 +17,158 +9.5% $2.73 196,992 07 Jul 2022 Direct F1
transaction FATE Common Stock Sale $518,686 -17,158 -8.7% $30.23* 179,834 07 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $46,841 -17,158 -57% $2.73 13,156 07 Jul 2022 Common Stock 17,158 $2.73 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold ranging from $30.00 to $30.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range set forth in footnote 2.
F3 This option is fully vested.